GW Pharma (GWPH) Posts Q3 Loss as Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
GW Pharma (GWPH) PT Lowered to $160 at Leerink Partners
August 8, 2017 10:23 AM EDTLeerink Partners lowered its price target on GW Pharma (NASDAQ: GWPH) to $160.00 (from $162.00) while maintaining a Outperform rating. GWPH announced 3Q EPS of (£0.13) which were in line with estimates of (£0.14).
GWPH has begun the rolling submission process for its Epidiolex filing and... More
